



## Relationship Between Urinary Sodium Excretion Over Time and Mortality in Type 2 Diabetes

*Diabetes Care* 2014;37:e62–e63 | DOI: 10.2337/dc13-1947

Elif I. Ekinci,<sup>1,2,3</sup> John L. Moran,<sup>4</sup> Merlin C. Thomas,<sup>5</sup> Karey Cheong,<sup>1</sup> Sophie Clarke,<sup>6</sup> Angela Chen,<sup>1</sup> Matt Dobson,<sup>1</sup> Amanda Leong,<sup>1</sup> Richard J. MacIsaac,<sup>7,8</sup> and George Jerums<sup>1,2</sup>

It remains unclear whether dietary salt intake over years (not just at baseline) influences hard outcomes. We have previously demonstrated an increased risk of mortality in patients with type 2 diabetes (T2D) and low baseline 24-h urinary sodium excretion (24hU<sub>Na</sub>) (1). Based on the same cohort of patients, the aim of the current study was to examine the relationship among serial measurements of 24hU<sub>Na</sub>, estimated glomerular filtration rate (eGFR), and all-cause mortality, adjusting for covariates associated with 24hU<sub>Na</sub> and eGFR.

This was a prospective cohort study of patients with T2D attending a single tertiary hospital diabetes clinic, initiated in mid-2000 with follow-up completed in 2010 (1). Serial 24hU<sub>Na</sub> (mmol/24 h) and eGFR (mL/min/1.73 m<sup>2</sup>) measurements were performed at regular intervals. The impact of 24hU<sub>Na</sub> and eGFR over time on all-cause mortality was determined by a joint model of longitudinal (linear-mixed model) and time-to-event (Weibull parametric survival model) data.

Follow-up 24hU<sub>Na</sub> and eGFR data from 588 patients were used in the current analysis. There were 152 deaths (26%)

after a median follow-up of 9 years. Significant predictors of eGFR in the linear-mixed model were baseline eGFR and BMI, age, sex, follow-up time (years), and 24hU<sub>Na</sub> and albumin excretion rate over time. Survival model predictors were sex, 24hU<sub>Na</sub>, and eGFR over time; baseline eGFR; diastolic blood pressure; presence of congestive heart failure and/or atrial fibrillation; and duration of diabetes.

The relationship between all-cause mortality and 24hU<sub>Na</sub> (adjusted for covariates) is demonstrated in Fig. 1, where an increase in all-cause mortality was evident in those with lower 24hU<sub>Na</sub>. Predicted survival at 9.5 years ranged from 94% (24hU<sub>Na</sub> = 264 mmol/24 h; 90th percentile) to 77.5% (24hU<sub>Na</sub> = 96 mmol/24 h; 10th percentile).

Low 24hU<sub>Na</sub> was associated with increased all-cause mortality, allowing for changes in 24hU<sub>Na</sub> and eGFR over time, consistent with the original study findings (1).

Limitations are recognized. Observational data presented here are restricted to patients with long-standing T2D and our analysis is hypothesis-generating rather than identifying a direct causal relationship. Furthermore,

observational studies may be subject to confounding.

The strengths are the use of multiple 24hU<sub>Na</sub> measurements to estimate dietary salt intake over time in each individual and the use of a joint model for statistical analysis (2,3). Joint modeling has not been previously used to predict mortality in cohort studies of dietary salt intake and has the advantage that over time repeated measurements can reduce measurement error and overcome the effect of treatment of covariates (4).

Low 24hU<sub>Na</sub> excretion over time was associated with increased mortality in people with T2D. The study findings are in line with the Institute of Medicine report (5) no longer recommending lowering sodium intake to ≤65 mmol/24 h in patients with diabetes. These findings call for research on the effects of habitual low salt intake on markers of renin-angiotensin-aldosterone system activity, endothelial function, and sympathetic nervous system activity in people with diabetes. Studies, now in progress, should help to resolve the question of whether low dietary salt intake is a pathogenetic factor, as opposed to a marker, for cardiovascular or renal events in diabetes.

<sup>1</sup>Austin Health Endocrine Centre, Heidelberg Repatriation Hospital, Heidelberg West, Melbourne, Australia

<sup>2</sup>Department of Medicine Austin Health, The University of Melbourne, Melbourne, Australia

<sup>3</sup>Preventable Chronic Diseases Division, Menzies School of Health Research, Darwin, Australia

<sup>4</sup>Department of Intensive Care Medicine, The Queen Elizabeth Hospital and Health Service, Adelaide, Australia

<sup>5</sup>Division of Diabetes Complications, Baker IDI Heart and Diabetes Institute, Melbourne, Australia


<sup>6</sup>Department of Endocrinology, Nambour Hospital, Nambour, Australia

<sup>7</sup>Department of Diabetes and Endocrinology, St. Vincent's Hospital, Fitzroy, Australia

<sup>8</sup>Department of Medicine, The University of Melbourne, St. Vincent's Health, Melbourne, Australia

Corresponding author: Elif I. Ekinci, elif.ekinci@unimelb.edu.au.

© 2014 by the American Diabetes Association. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.



**Figure 1**—All-cause mortality across percentiles of  $24hU_{Na}$  (mmol/24 h), averaged over covariate effect. All-cause mortality: effect of percentiles of  $24hU_{Na}$  (mmol/24 h), taking into account longitudinal measurements of  $24hU_{Na}$  and eGFR throughout the study period. Survival by percentiles of  $24hU_{Na}$ : other predictors held at mean value. Joint model of longitudinal (eGFR) and survival (all-cause mortality) data (95% CI). 10th percentile (96 mmol/24 h) is represented by ----; 25th percentile (128 mmol/24 h), - . - . -; 50th percentile (168 mmol/24 h), .....; 75th percentile (216 mmol/24 h), — — —; and 90th percentile (264 mmol/24 h), - - - - -.

**Acknowledgments.** The authors thank the Australian Institute of Health and Welfare for assistance during data collection for this project.

**Funding and Duality of Interest.** E.I.E. was supported by a National Health and Medical Research Council (NHMRC) Medical Postgraduate Scholarship, Austin Hospital Medical Research Fund (AHMRF), and NHMRC Early Career Fellowship (#1054312). E.I.E. and S.C. were both recipients of a Cardiovascular Lipid Research Grant from Pfizer for unconditional use of funding for research projects. S.C. was supported by AHMRF during data collection. No other potential conflicts of interest relevant to this article were reported.

**Author Contributions.** E.I.E., J.L.M., and G.J. designed the current study. E.I.E. wrote the

manuscript and researched data. J.L.M. performed statistics. M.C.T., K.C., S.C., A.C., M.D., and A.L. researched data. J.L.M., G.J., and R.J.M. edited the manuscript. E.I.E. and J.L.M. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Prior Presentation.** This study was presented in abstract form at the 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL, 21–25 June 2013.

## References

- Ekinci EI, Clarke S, Thomas MC, et al. Dietary salt intake and mortality in patients with type 2 diabetes. *Diabetes Care* 2011;34:703–709
- Holbrook JT, Patterson KY, Bodner JE, et al. Sodium and potassium intake and balance in adults consuming self-selected diets. *Am J Clin Nutr* 1984;40:786–793
- Crowther MJ, Abrams KR, Lambert P. Joint modeling of longitudinal and survival data. *The Stata Journal* 2013;13:165–184
- Ibrahim JG, Chu H, Chen LM. Basic concepts and methods for joint models of longitudinal and survival data. *J Clin Oncol* 2010;28:2796–2801
- Committee on the Consequences of Sodium Reduction in Populations, Food and Nutrition Board, Board on Population Health and Public Health Practice, Institute of Medicine. Sodium intake in populations: assessment of evidence. Strom BL, Yaktine AL, Oria M, Eds. Washington, DC, The National Academies Press, 2013